Bellevue Group Ag Neurocrine Biosciences Inc Transaction History

Bellevue Group Ag

$5.98 Billion
Q2 2024

A detailed history of Bellevue Group Ag transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bellevue Group Ag holds 1,898,640 shares of NBIX stock, worth $218 Million. This represents 4.37% of its overall portfolio holdings.

Number of Shares

1,898,640

Previous 2,055,874 7.65%

Holding current value

$218 Million

Previous $284 Million 7.82%

% of portfolio

4.37%

Previous 4.44%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $20.6 Million - $22.5 Million	-157,234 Reduced 7.65%	1,898,640 $261 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $48.9 Million - $53.8 Million	-374,626 Reduced 15.41%	2,055,874 $284 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $16.2 Million - $20.3 Million	-153,050 Reduced 5.92%	2,430,500 $320 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $2.75 Million - $3.43 Million	-29,250 Reduced 1.12%	2,583,550 $291 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $44,765 - $52,435	-500 Reduced 0.02%	2,612,800 $246 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $15.1 Million - $19.7 Million	-159,994 Reduced 5.77%	2,613,300 $265 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $8.74 Million - $10.4 Million	-81,852 Reduced 2.87%	2,773,294 $331 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $997,697 - $1.17 Million	10,841 Added 0.38%	2,855,146 $303 Million
Q2 2022 Aug 11, 2022	SELL	$75.79 - $100.07 $13.6 Million - $17.9 Million	-179,146 Reduced 5.93%	2,844,305 $277 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $11.4 Million - $14.9 Million	-157,100 Reduced 4.94%	3,023,451 $283 Million
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $14.1 Million - $18.7 Million	176,500 Added 5.88%	3,180,551 $271 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $1.18 Million - $1.36 Million	-13,700 Reduced 0.45%	3,004,051 $288 Million
Q2 2021 Aug 12, 2021	SELL	$89.43 - $102.27 $23 Million - $26.3 Million	-256,800 Reduced 7.84%	3,017,751 $294 Million
Q1 2021 May 12, 2021	SELL	$87.57 - $119.4 $10.7 Million - $14.6 Million	-122,100 Reduced 3.59%	3,274,551 $318 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $8.62 Million - $10.7 Million	99,200 Added 3.01%	3,396,651 $326 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $8.32 Million - $11.7 Million	86,551 Added 2.7%	3,297,451 $317 Million
Q2 2020 Aug 13, 2020	SELL	$85.09 - $130.36 $4.13 Million - $6.33 Million	-48,574 Reduced 1.49%	3,210,900 $392 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $4.42 Million - $6.7 Million	-58,900 Reduced 1.77%	3,259,474 $282 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $1.73 Million - $2.36 Million	19,900 Added 0.6%	3,318,374 $357 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $20.8 Million - $25.2 Million	-247,970 Reduced 6.99%	3,298,474 $297 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $255 Million - $322 Million	3,526,244 Added 17456.65%	3,546,444 $299 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $1.38 Million - $1.82 Million	-19,850 Reduced 49.56%	20,200 $1.78 Million
Q4 2018 Feb 12, 2019	SELL	$68.32 - $124.36 $102,479 - $186,540	-1,500 Reduced 3.61%	40,050 $2.86 Million
Q3 2018 Nov 13, 2018	SELL	$98.88 - $125.85 $197,760 - $251,700	-2,000 Reduced 4.59%	41,550 $5.11 Million
Q2 2018 Aug 07, 2018	SELL	$75.3 - $105.99 $760,530 - $1.07 Million	-10,100 Reduced 18.83%	43,550 $4.28 Million
Q1 2018 May 09, 2018	SELL	$75.88 - $92.43 $64,497 - $78,565	-850 Reduced 1.56%	53,650 $4.45 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $87,795 - $116,385	-1,500 Reduced 2.68%	54,500 $4.23 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $431,730 - $551,520	9,000 Added 19.15%	56,000 $3.43 Million
Q2 2017 Aug 14, 2017	BUY	N/A	47,000	47,000 $2.16 Million

Others Institutions Holding NBIX

# of Institutions

641

Shares Held

95.3M

Call Options Held

661K

Put Options Held

227K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Neurocrine Biosciences Inc Transaction History